Human Genetics

, Volume 123, Issue 3, pp 247–255 | Cite as

Genetic variation in IGFBP2 and IGFBP5 is associated with breast cancer in populations of African descent

  • Chad P. Garner
  • Yuan C. Ding
  • Esther M. John
  • Sue A. Ingles
  • Olufunmilayo I. Olopade
  • Dezheng Huo
  • Clement Adebamowo
  • Temidayo Ogundiran
  • Susan L. Neuhausen
Original Investigation

Abstract

The insulin-like growth factor (IGF) signaling pathway is thought to play a major role in the etiology of breast cancer. Although incidence rates of breast cancer overall are lower in African Americans than in Caucasians, African-American women have a higher incidence under age 40 years, are diagnosed with more advanced disease, and have poorer prognosis. We investigated the association of breast cancer and genetic variants in genes in the IGF signaling pathway in a population-based case–control study of African-American women. We found significant associations at a locus encompassing parts of the IGFBP2 and IGFBP5 genes on chromosome 2q35, which we then replicated in a case–control study of Nigerian women. Based on those initial findings, we genotyped a total of 34 single nucleotide polymorphisms (SNPs) across the region in both study populations. Statistically significant associations with breast cancer were observed across approximately 50 kb of DNA sequence encompassing three exons in the 3′ end of IGFBP2 and three exons in the 3′ end of IGFBP5. SNPs were associated with breast cancer risk with P values as low as P = 0.0038 and P = 0.01 in African-Americans and Nigerians, respectively. This study is the first to report associations between genetic variants in IGFBP2 and IGFBP5 and breast cancer risk.

Notes

Acknowledgments

We thank Jocelyn Koo for data management and Karen Kelly and Megan Rounds for genotyping, and Kavita Renduchintala, Ming Li, and Aileen Sy for help with the genotyping. We thank the women who participated in this research. This work was supported by the California Breast Cancer Program 9PB-0142 (to SLN). The multi-ethnic case-control study was supported by grant CA77305 from the National Cancer Institute (NCI) and grant 17-96-1-6071 by the U.S. Department of Defense (to EMJ). The Northern California Family Registry for Breast Cancer was supported by the NCI under RFA#CA95-003 through a cooperative agreement with the Northern California Cancer Center (to EMJ). Collection of the Nigerian case-control population was funded by NCI CA-RO1 89085-01A and the Ralph and Marion Falk Medical Research Trust (to OIO).

References

  1. Adebamowo CA, Ogundiran TO, Adenipekun AA, Oyesegun RA, Campbell OB, Akang EU, Rotimi CN, Olopade OI (2003) Obesity and height in urban Nigerian women with breast cancer. Ann Epidemiol 13:455–461PubMedCrossRefGoogle Scholar
  2. Al-Zahrani A, Sandhu MS, Luben RN, Thompson D, Baynes C, Pooley KA, Luccarini C, Munday H, Perkins B, Smith P, Pharoah PD, Wareham NJ, Easton DF, Ponder BA, Dunning AM (2006) IGF1 and IGFBP3 tagging polymorphisms are associated with circulating levels of IGF1, IGFBP3 and risk of breast cancer. Hum Mol Genet 15:1–10PubMedCrossRefGoogle Scholar
  3. Armitage P (1955) Tests for linear trends in proportions and frequencies. Biometrics 11:375–386CrossRefGoogle Scholar
  4. Aziz H, Hussain F, Sohn C, Mediavillo R, Saitta A, Hussain A, Brandys M, Homel P, Rotman M (1999) Early onset of breast carcinoma in African American women with poor prognostic factors. Am J Clin Oncol 22:436–440PubMedCrossRefGoogle Scholar
  5. Beattie J, Allan GJ, Lochrie JD, Flint DJ (2006) Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis. Biochem J 395:1–19PubMedCrossRefGoogle Scholar
  6. Becker M, Sommer A, Kratzschmar JR, Seidel H, Pohlenz HD, Fichtner I (2005) Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4:151–168PubMedGoogle Scholar
  7. Bohlke K, Cramer DW, Trichopoulos D, Mantzoros CS (1998) Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 9:570–573PubMedCrossRefGoogle Scholar
  8. Bruning PF, Van Doorn J, Bonfrer JM, Van Noord PA, Korse CM, Linders TC, Hart AA (1995) Insulin-like growth-factor-binding protein 3 is decreased in early-stage operable pre-menopausal breast cancer. Int J Cancer 62:266–270PubMedCrossRefGoogle Scholar
  9. Busund LT, Richardsen E, Busund R, Ukkonen T, Bjornsen T, Busch C, Stalsberg H (2005) Significant expression of IGFBP2 in breast cancer compared with benign lesions. J Clin Pathol 58:361–366PubMedCrossRefGoogle Scholar
  10. Butt AJ, Dickson KA, McDougall F, Baxter RC (2003) Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem 278:29676–29685PubMedCrossRefGoogle Scholar
  11. Butt AJ, Dickson KA, Jambazov S, Baxter RC (2005) Enhancement of tumor necrosis factor-alpha-induced growth inhibition by insulin-like growth factor-binding protein-5 (IGFBP-5), but not IGFBP-3 in human breast cancer cells. Endocrinology 146:3113–3122PubMedCrossRefGoogle Scholar
  12. Byrne C, Hankinson SE, Pollak M, Willett WC, Colditz GA, Speizer FE (2000) Insulin-like growth factors and mammographic density. Growth Horm IGF Res 10(Suppl A):S24–5PubMedCrossRefGoogle Scholar
  13. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, Palli D, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R (2006) Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. Br J Cancer 94:299–307PubMedCrossRefGoogle Scholar
  14. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA (2004) Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 74:106–120PubMedCrossRefGoogle Scholar
  15. Chapman J, Clayton D (2007) One degree of freedom for dominance in indirect association studies. Genet Epidemiol 31:261–271PubMedCrossRefGoogle Scholar
  16. Cheng I, Penney KL, Stram DO, Le Marchand L, Giorgi E, Haiman CA, Kolonel LN, Pike M, Hirschhorn J, Henderson BE, Freedman ML (2006) Haplotype-based association studies of IGFBP1 and IGFBP3 with prostate and breast cancer risk: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:1993–1997PubMedCrossRefGoogle Scholar
  17. Cleveland RJ, Gammon MD, Edmiston SN, Teitelbaum SL, Britton JA, Terry MB, Eng SM, Neugut AI, Santella RM, Conway K (2006) IGF1 CA repeat polymorphisms, lifestyle factors and breast cancer risk in the Long Island Breast Cancer Study Project. Carcinogenesis 27:758–765PubMedCrossRefGoogle Scholar
  18. Deming SL, Ren Z, Wen W, Shu XO, Cai Q, Gao YT, Zheng W (2007) Genetic variation in IGF1, IGF-1R, IGFALS, and IGFBP3 in breast cancer survival among Chinese women: a report from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 104:309–319PubMedCrossRefGoogle Scholar
  19. English WP, Cleveland KE, Barber WH (2002) There is no difference in survival between African-American and white women with breast cancer. Am Surg 68:594–597PubMedGoogle Scholar
  20. Flint DJ, Beattie J, Allan GJ (2003) Modulation of the actions of IGFs by IGFBP-5 in the mammary gland. Horm Metab Res 35:809–815PubMedCrossRefGoogle Scholar
  21. Frommer KW, Reichenmiller K, Schutt BS, Hoeflich A, Ranke MB, Dodt G, Elmlinger MW (2006) IGF-independent effects of IGFBP-2 on the human breast cancer cell line Hs578T. J Mol Endocrinol 37:13–23PubMedCrossRefGoogle Scholar
  22. Gonzalez-Zuloeta Ladd AM, Liu F, Houben MP, Arias Vasquez A, Siemes C, Janssens AC, Coebergh JW, Hofman A, Janssen JA, Stricker BH, van Duijn CM (2007) IGF-1 CA repeat variant and breast cancer risk in postmenopausal women. Eur J Cancer 43:1718–1722PubMedCrossRefGoogle Scholar
  23. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M (1998) Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393–1396PubMedCrossRefGoogle Scholar
  24. Jernstrom H, Chu W, Vesprini D, Tao Y, Majeed N, Deal C, Pollak M, Narod SA (2001) Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: implications for premenopausal breast cancer risk. Mol Genet Metab 72:144–154PubMedCrossRefGoogle Scholar
  25. Jerome L, Shiry L, Leyland-Jones B (2003) Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions. Endocr Relat Cancer 10:561–578PubMedCrossRefGoogle Scholar
  26. John EM, Horn-Ross PL, Koo J (2003) Lifetime physical activity and breast cancer risk in a multiethnic population: the San Francisco Bay area breast cancer study. Cancer Epidemiol Biomarkers Prev 12:1143–1152PubMedGoogle Scholar
  27. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, Ziogas A, Andrulis IL, Anton-Culver H, Boyd N, Buys SS, Daly MB, O’Malley FP, Santella RM, Southey MC, Venne VL, Venter DJ, West DW, Whittemore AS, Seminara D (2004) The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 6:R375–R389PubMedCrossRefGoogle Scholar
  28. Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34PubMedCrossRefGoogle Scholar
  29. Marbella AM, Layde PM (2001) Racial trends in age-specific breast cancer mortality rates in US women. Am J Public Health 91:118–121PubMedGoogle Scholar
  30. Marshman E, Green KA, Flint DJ, White A, Streuli CH, Westwood M (2003) Insulin-like growth factor binding protein 5 and apoptosis in mammary epithelial cells. J Cell Sci 116:675–682PubMedCrossRefGoogle Scholar
  31. Martin JL, Baxter RC (2007) Expression of insulin-like growth factor binding protein-2 (IGFBP-2) by MCF-7 breast cancer cells is regulated through the PI3-KINASE/AKT/mTOR pathway. Endocrinology 148:2532–2541PubMedCrossRefGoogle Scholar
  32. Maxwell P, van den Berg HW (1999) Changes in the secretion of insulin-like growth factor binding proteins-2 and -4 associated with the development of tamoxifen resistance and estrogen independence in human breast cancer cell lines. Cancer Lett 139:121–127PubMedCrossRefGoogle Scholar
  33. Missmer SA, Haiman CA, Hunter DJ, Willett WC, Colditz GA, Speizer FE, Pollak MN, Hankinson SE (2002) A sequence repeat in the insulin-like growth factor-1 gene and risk of breast cancer. Int J Cancer 100:332–336PubMedCrossRefGoogle Scholar
  34. Mohan S, Baylink D (2002) IGF-binding proteins are multifunctional and act via IGF-dependent and -independent mechanisms. J Endocrinol 175:19–31PubMedCrossRefGoogle Scholar
  35. Pereira JJ, Meyer T, Docherty SE, Reid HH, Marshall J, Thompson EW, Rossjohn J, Price JT (2004) Bimolecular interaction of insulin-like growth factor (IGF) binding protein-2 with alphavbeta3 negatively modulates IGF-I-mediated migration and tumor growth. Cancer Res 64:977–984PubMedCrossRefGoogle Scholar
  36. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4:505–518PubMedCrossRefGoogle Scholar
  37. Ren Z, Cai Q, Shu XO, Cai H, Li C, Yu H, Gao YT, Zheng W (2004) Genetic polymorphisms in the IGFBP3 gene: association with breast cancer risk and blood IGFBP-3 protein levels among Chinese women. Cancer Epidemiol Biomarkers Prev 13:1290–1295PubMedGoogle Scholar
  38. Ries L, Eisner M, Kosary C, Hankey B, Miller B, Clegg L, Mariotto A, Feuer E, Edwards B (2004) SEER Cancer Statistics Review, 1975–2001. National Cancer Institute, BethesdaGoogle Scholar
  39. Rosenzweig SA (2004) What’s new in the IGF-binding proteins? Growth Horm IGF Res 14:329–336PubMedCrossRefGoogle Scholar
  40. Sachdev D, Yee D (2001) The IGF system and breast cancer. Endocr Relat Cancer 8:197–209PubMedCrossRefGoogle Scholar
  41. Sasieni PD (1997) From genotypes to genes: doubling the sample size. Biometrics 53:1253–1261PubMedCrossRefGoogle Scholar
  42. Schernhammer ES, Hankinson SE, Hunter DJ, Blouin MJ, Pollak MN (2003) Polymorphic variation at the −202 locus in IGFBP3: Influence on serum levels of insulin-like growth factors, interaction with plasma retinol and vitamin D and breast cancer risk. Int J Cancer 107:60–64PubMedCrossRefGoogle Scholar
  43. Schutt BS, Langkamp M, Rauschnabel U, Ranke MB, Elmlinger MW (2004) Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells. J Mol Endocrinol 32:859–868PubMedCrossRefGoogle Scholar
  44. Setiawan VW, Cheng I, Stram DO, Penney KL, Le Marchand L, Altshuler D, Kolonel LN, Hirschhorn J, Henderson BE, Freedman ML (2006) Igf-I genetic variation and breast cancer: the multiethnic cohort. Cancer Epidemiol Biomarkers Prev 15:172–174PubMedCrossRefGoogle Scholar
  45. Swanson GM, Lin CS (1994) Survival patterns among younger women with breast cancer: the effects of age, race, stage, and treatment. J Natl Cancer Inst Monogr 69–77Google Scholar
  46. Toniolo P, Bruning PF, Akhmedkhanov A, Bonfrer JM, Koenig KL, Lukanova A, Shore RE, Zeleniuch-Jacquotte A (2000) Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828–832PubMedCrossRefGoogle Scholar
  47. Trock BJ (1996) Breast cancer in African American women: epidemiology and tumor biology. Breast Cancer Res Treat 40:11–24PubMedCrossRefGoogle Scholar
  48. Wagner K, Hemminki K, Israelsson E, Grzybowska E, Soderberg M, Pamula J, Pekala W, Zientek H, Mielzynska D, Siwinska E, Forsti A (2005) Polymorphisms in the IGF-1 and IGFBP 3 promoter and the risk of breast cancer. Breast Cancer Res Treat 92:133–140PubMedCrossRefGoogle Scholar
  49. Wang W, John EM, Ingles SA (2005) Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol Biomarkers Prev 14:2990–2994PubMedCrossRefGoogle Scholar
  50. Wong WW, Copeland KC, Hergenroeder AC, Hill RB, Stuff JE, Ellis KJ (1999) Serum concentrations of insulin, insulin-like growth factor-I and insulin-like growth factor binding proteins are different between white and African American girls. J Pediatr 135:296–300PubMedCrossRefGoogle Scholar
  51. Yanovski JA, Sovik KN, Nguyen TT, Sebring NG (2000) Insulin-like growth factors and bone mineral density in African American and White girls. J Pediatr 137:826–32PubMedCrossRefGoogle Scholar
  52. Yu H, Jin F, Shu XO, Li BD, Dai Q, Cheng JR, Berkel HJ, Zheng W (2002) Insulin-like growth factors and breast cancer risk in Chinese women. Cancer Epidemiol Biomarkers Prev 11:705–712PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Chad P. Garner
    • 1
  • Yuan C. Ding
    • 1
  • Esther M. John
    • 2
  • Sue A. Ingles
    • 3
  • Olufunmilayo I. Olopade
    • 4
  • Dezheng Huo
    • 5
  • Clement Adebamowo
    • 6
  • Temidayo Ogundiran
    • 6
  • Susan L. Neuhausen
    • 1
  1. 1.Department of EpidemiologyUniversity of California IrvineIrvineUSA
  2. 2.Northern California Cancer CenterFremontUSA
  3. 3.Keck School of MedicineUniversity of Southern CaliforniaLos AngelesUSA
  4. 4.Department of MedicineUniversity of ChicagoChicagoUSA
  5. 5.Department of Health StudiesUniversity of ChicagoChicagoUSA
  6. 6.Department of Surgery, Division of Oncology, College of MedicineUniversity of IbadanIbadanNigeria

Personalised recommendations